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OKY-1581,  a new th romboxane  synthetase inhibitor,  was studied in a conscious canine model of coronary 
thrombosis .  After  thoracotomy with placement  of a left circumflex coronary artery flow probe  and implanta t ion  of an 
electrode into the circumflex artery, animals  were assigned randomly to the following groups: 0.9% NaCI vehicle 
control  or OKY-1581 1 m g / k g  every 4 h intravenously for 24 h. During the drug t rea tment  period, a 50 txA anodal  
current  was passed through the circumflex electrode, and venous blood was obta ined  for platelet aggregation studies. 
As compared  to control  animals,  the OKY-1581 treated animals  developed a greater mean coronary flow at the end of 
the t reatment  period, smaller th rombi  by wet weight, smaller infarcts, and  fewer ventr icular  arrhythmias.  Ex vivo 
platelet  aggregation studies revealed significant inhibi t ion of aggregation to s tandard  aggregating agents for the drug 
treated group only. OKY-1581 is an effective an t i tb rombot ic  agent which main ta ins  coronary flow after a th rombo-  
genic stimulus, presumably via blockade of the synthesis of th romboxane  by blood platelets. 
Coronary  artery thrombosis  T h r om boxane  synthetase inhibi tor  Platelet aggregation Ant i th rombot i c  agent 
!. Introduction hibition of thromboxane production may result in 
the utilization of platelet cyclic endoperoxides by 
Recent antithrombotic strategies have era- the vascular endothelium with an increase in pros- 
phasized inhibition of selected platelet functions tacyclin production (Marcus et al., 1980). 
including aggregation, adhesion and production of Several drugs have been reported as inhibitors 
vasoactive metabolites of the arachidonic acid of thromboxane synthetase, principally imidazole 
pathway, e.g. thromboxane A 2 (Moncada and and its derivatives (Moncada et al., 1977; Tai and 
Vane, 1979; Packham and Mustard, 1980). An Yuan, 1978). One of the imidazoles, dazoxiben, 
appealing approach is thromboxane synthetase in- has been studied extensively in the laboratory and 
hibition with a resultant decrease in thromboxane in man and has shown promise in conditions 
generation by blood platelets and circulating ranging from angina pectoris to endotoxemia 
leukocytes, thereby leaving the endothelial pros- (Anonymous, 1983). Preliminary studies with 
tacyclin production presumably intact. Indeed, in- OKY-1581 (sodium (E)-3-[4-(3-pyridylmethyl) 
phenyl]-2-methylacrylate) and its hydrochloride 
salt, OKY-1555, have indicated that they are potent 
and selective inhibitors of thromboxane synthetase 
in experimental systems involving PGH 2 and in- * To whom all correspondence should be addressed: Depart- 
ment of Pharmacology, M6322 Medical Science Building I, cubated rabbit platelets (Feuerstein and Ramwell, 
University of Michigan Medical School, Ann Arbor, Michi- 1981) and lipopolysaccharide stimulated ra t  m a c -  
gan 48109, U.S.A. rophages (Miyamoto et al.. 1980). 
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Using a canine model of coronary artery 2.2. Electrical stimulation of the circumflex artery 
thrombosis recently developed in our laboratory and drug treatment 
(Romson et al., 1980). we hypothesized that the 
antiplatelet effect of OKY-1581 might limit Twenty-four h after the completion of surgery. 
coronary thrombosis thereby lessening the subsc- the animal's heart rate, blood pressure, electro- 
quent adverse events of myocardial infarction and cardiogram, and coronary blood flow were moni- 
arrhythmia generation, tored. Animals were studied further only if: (1) 
they were free of electrocardiographic evidence of 
myocardial injury and /o r  necrosis, (2) they had no 
2. Materials and methods evidence of significant arrhythmias (fewer than 5 
premature ventricular complexes per min), (3) they 
had a normal phasic pattern of coronary blood 
2.1. Surgical procedure flow. The animals were returned to their respective 
kennels and the study protocol was initiated on 
Male mongrel dogs, 15-20 kg, were anesthetized the second postoperative day if the above stated 
with intravenous sodium pentobarbital (30 mg/kg)  criteria were satisfied. 
and artificially ventilated. A lead II electrocardio- The experimental protocol, briefly outlined, was 
gram (ECG) was monitored throughout surgery, as follows. Day 1: surgery: day 2: recovery; day 3: 
Using aseptic technique, cannulae were placed in venous blood for platelet aggregation, treatment 
the left common carotid artery and jugular vein with drug or vehicle control every 4 h for 24 h, 
and exteriorized through the nape of the neck. electrical stimulation of the LCX for 24 h with 
After a left thoracotomy, the heart was suspended concomitant ECG monitoring, venous blood for 
in a pericardiai cradle and the proximal left cir- platelet aggregation after the second dose of drug 
cumflex coronary artery (LCX) was isolated from (during electrical stimulation of the LCX), day 4: 
the surrounding tissues. A 28 gauge Teflon-coated venous blood for platelet aggregation; sacrifice. 
silver wire with 5 mm of the tip of a 25 gauge Animals were given 0.9% NaCI or OKY-1581 
hypodermic needle secured on the wire's leading according to a random numbers table. OKY-1581, 
end was inserted into the LCX and affixed to the 1 mg/kg,  (Ono Pharmaceutical Co., Osaka, Japan) 
heart with two superficial 3-0 silk epicardial su- was administered to the animals every 4 h in- 
tures. A pre-calibrated electromagnetic flow probe travenously for the next 24 h. 
(Carolina Instrument Co.) was placed on the LCX After the initial dose of drug or 0.9% Na('l. 
2-3 mm proximal to the silver wire insertion and anodal current from a 9V battery was delivered to 
affixed to the epicardial surface of the heart with the intimal surface of the LCX via the Teflon- 
2-0 silk suture. The zero flow baseline was estab- coated wire. The current output of 50 p.A was 
lishcd by transient total occlusion of the LCX adjusted through a 250000 ~'1 potentiometer placed 
followed by release. Coronary blood flow was in series. The ECG electrode leads were connected 
measured with a square-wave electromagnetic flow to a telemetry transmitter. The potentiometer with 
meter (Carolina Medical Electronics, Inc.). The the battery supply and ECG transmitter were kept 
pericardium and chest were closed in layers. Grass in a nylon jacket which allowed the dog unre- 
disc electrodes were tunneled subcutaneously near stricted movement. 
the right foreleg and left hindleg and exteriorized Electrocardiographic data were received via re- 
along with the intracoronary wire and flow probe lemetry and in turn were recorded on a tape 
through the thoracotomy incision. The dogs were recorder programmed to record 28 s of tracing 
given a single intramuscular injection of ampicillin cvery 15 min. The tape was played back later 
(3 mg/kg).  Cannulae were flushed with 0.9% NaCI through a Grass model 7 oscillographic recorder 
and a dilute porcine heparin solution (50 units in for analysis of arrhythmias, 
0.3 ml) (Sigma) was placed in the cannulae to The 50 tzA current to the LCX was continued 
maintain patency, for 24 h (while drug dosing was continuing). 
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Venous b lood for platelet  s tudies was ob ta ined  fract ion.  Platelet  rich p lasma was di luted with 
af ter  the second drug  admin i s t r a t ion  interval  dur-  p la te le t  poor  p lasma  to a platelet  count  of  
ing the per iod of electr ical  s t imula t ion  and again 2 0 0 0 0 0 / m m  s before  use in the aggregat ion assays. 
at the end of  the electr ical  s t imula t ion  at 24 h. The  All platelet  samples  were assayed within 2 h of  the 
an imals  were moni to red  for 30 rain for heart  rate, t ime of b lood collection.  Aggregat ion  was ini t ia ted 
b lood  pressure,  e l ec t roca rd iogram and coronary  under  3 different  condi t ions  using a 50 ~1 al iquot  
b lood  flow by direct  recording on a Grass  model  7 of  aggregat ing agent added  to 450 ~1 of  d i lu ted  
osc i l lographic  recorder .  The animals  then were p la te le t  rich plasma.  Aggregat ing  stimuli included:  
anes thet ized with 30 m g / k g  of sod ium pen toba r -  col lagen ( 1 : 8 0  di lut ion of Ethicon Col lagen Dis- 
bi ta l  and the heart  was exposed as descr ibed  above,  pers ion - TDI50) ;  5.0 ttg A D P  (Sigma); and 
Ventr icular  f ibr i l la t ion was induced by a DC cur- a rachidonic  acid (Sigma) 0.65 mM with an addi -  
rent and the heart  was removed.  The LCX in the t ional  10 ~tl of L-ep inephr ine  (Sigma), 0.55 t tM in 
area  of  the wire inser t ion was dissected free and saline at p H  3. 
the ar tery was opened  lengthwise. The wet T h r o m b o x a n e  measurements  were not  made  in 
th rombus  was removed intact  from the in t ima and this study. 
weighed. The  heart  then was " ' b read loa fed"  from 
apex to base into 7 mm thick t ransverse slices and 2.4. Statistical methods" 
incubated  in 2 ,3 ,5- t r iphenyl te t razol ium chlor ide  
(TTC)  (Sigma) for 30 min at 37°C .  TTC stains All  da ta  are expressed as the mean + s t andard  
normal  tissues brick red due to the formazan dye error  of the mean.  The S tudent ' s  t-test for un- 
resul t ing from the reduct ion of TTC by the dehy-  pa i red  observat ions  was used to evaluate  the statis- 
drogenases  of viable  myocard ium.  The irreversibly tical s ignificance of  the hemodynamic  and infarct  
in jured areas  do  not  react with TTC and appea r  as da ta  (Reming ton  and Schork, 1970). The Mann-  
pale  gray regions which are  d is t inguished easily for Whi tney  test was used to evaluate  the stat is t ical  
purposes  of  quant i f ica t ion.  Both the nons ta ined  signif icance of  the a r rhy thmia  and platelet  aggre- 
and  s ta ined areas  were removed and weighed to gat ion da ta  (Conover ,  1980). A P value of < 0.05, 
permi t  ca lcula t ion  of infarct  mass which is cx- t reated vs. control ,  was considered to be statist i-  
pressed as a percent  of the total  left ventr icle by t a l ly  significant.  
weight.  
Sham opera ted  controls  with p lacement  of  the 
wire e lec t rode  and add i t iona l  ins t rumenta t ion  were 3. Results  
not  used for this s tudy.  Previous work (Romson  et 
al., 1980, and  unpubl i shed  observat ions)  suggests OKY-1581 had no signif icant  effect on heart  
that  sham opera ted  animals  do  not  spon taneous ly  rate,  b lood pressure,  the e lec t rocard iogram,  or  
develop  occlusive thrombi ,  myocard ia l  infarc t ion coronary  b lood flow when admin i s te red  acutely.  
or  a r rhy thmias  as a result of  the ins t rumenta t ion .  At  the end of the 24 h per iod of  drug adminis t ra -  
t ion and electrical  s t imulat ion,  the mean arter ial  
2.3. Platelet aggregation studies blood pressures for both  drug and control  groups  
had decreased.  Before OKY-1581 admin i s t ra t ion  
Platelet  aggregat ion  studies were pe r fo rmed  the mean arter ial  pressure was 1 1 1 _  6 mmHg,  
using previously  descr ibed spec t ropho tomet r i c  whereas  at the end of the exper iment  b lood pres- 
methods  (Romson  et al., 1980) uti l izing a B i o / D a t a  sure was 93 + 10 mmHg.  Observa t ions  were com- 
pla te le t  aggregometer .  Platelet  rich p lasma  was plete  for only  five of the seven animals  studied.  
p repa red  by col lect ing foreleg venous b lood  in 1.0 Fo r  the control  group the basel ine b lood pressure 
ml of 3.8% sod ium ci t ra te  to a total  volume of  10 was 109 + 5 m m t t g ,  whereas at the comple t ion  of 
nal. This was centr i fuged at 310 × g for 3 min to the s tudy the b lood pressure was 104 + 3 m m H g  
ob ta in  the pla te le t  rich p lasma  fract ion and then (n = 11). 
at 2200 × g for 10 min to ob ta in  the pla te le t  poor  There  was no difference in the basel ine mean 
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coronary blood flows for the 0.9% NaCI treated or TABLE 2 
drug treated animals:  20.4 + 1.3 m l / m i n  vs. 22.1 Frequency of ventricular arrhythmias during the 24 h of electri- 
+ 1.1 m l / m i n ,  respectively. At the end of the cal stimulation of the circumflex artery 
experimental  period, mean coronary flow was sig- Pv(',/IIR (%)" 
nif icantly greater in the OKY-1581 treated group ('ontrol OKY-1581 
than the control group: 11.1 + 4 m l / m i n  vs. 2 + 1.6 In - 11) (n = 7) 
m l / m i n ,  respectively (P < 0.05, treated vs. control). 
0 -6h  4.6± 2.8h 1.7± 1.7 
In the control group nine of eleven animals  had an 7-12 h 29.3 + 9.6 11.4 + 7.7 
absence of LCX coronary blood flow at the end of 13-18 h 78.8 _+ 10.8 ~ 23.1 ± 15.5 ,t 
the study period. Of the remaining  two animals,  19-24 tl 98.1 + 1.4" 27.3_+ 17.6 '~ 
one had a modest reduction in LCX coronary flow " Premature ventricular contractions expressed as a percentage 
(24 tO 18 m l / m i n ) ,  whereas the other had a marked of the heart rate. h Mean + S.E.M. " n = 10. ,i p < 0.05 treated 
reduct ion (26 to 4 m l / m i n ) .  In the drug treated vs. control. 
group, LCX coronary flow was absent  in three of 
seven animals  at the end of the experimental  other drug and contrtol  animals,  there was no 
period, whereas the remaining  four animals  had direct relationship between thrombus size and in- 
essentially no change in coronary flow from the farct size. 
beg inning  to the end of the experimental  period Drug treated animals  had fewer ventricular  
(22 vs. 19.5 m l / m i n ) ,  arrhythmias over the last 12 h of the study period 
The size of the thrombi  in the drug treated than the control groups (table 2). This difference 
group was one-fourth  of that in the 0.9% NaC1 may, in part, be related to the time course of 
vehicle control  group (table 1). There was no ap- thrombus  formation.  In this experimental  model, 
parent  relationship between thrombus size and the coronary thrombosis  most frequently occurs dur- 
coronary blood flow: comparat ively small thrombi ing the 4th to l l t h  h of electrical s t imulat ion 
were occasionally noted to be associated with an (unpubl ished observations) with the subsequent  
absence of coronary blood flow, however, large progressivc development  of electrocardiographic 
thrombi were always occlusive, changes and dis turbances in cardiac rhythm. Major 
Left ventr icular  infarct ion was considerably differences in the control and treated groups might 
smaller in the drug treated group as compared to not be expected until  the last 12 h of stud),. 
the control  group (table l).  This observat ion also 
applied when infarct mass was expressed as a 
percentage of the left ventricle to correct for dif- I00 
ferences in heart weights. Drug treated animals  
with nonocclusive thrombi  and main tenance  of Z 80 ~ ~ ~ 0  
coronary flow had the smallest infarctions.  For the < 60  
h i  
IX: 
4 0  
(_9 
TABLE 1 <~ 
Effect of OKY-1581 on thrombus size and myocardial infarc- ~ 20  th h h 
tion after electrical injury of the circumflex artery 0 ~N~"hl " 
Control OKY-1581 COLLAGEN ADP ARACHIDONIC 
ACID 
( n = l l )  (n=7) 
Thrombus wet weight (mg) 21.8 + 3.7 " 5.0__+ 1.5 t, Fig. 1. Each bar represents the mean _+ S.E.M. (n = 6) from an 
I.eft ventricular infarction (g) 15.2+ 1.3 4.7+2.1 b aggregating condition at one of three time points: 0 h, the 
Left ventricle (g) 74.8 + 5.2 75.1 + 3.1 pre-drug baseline: 4 h, after the second dose of drug; and 24 h, 
Infarct/left ventricle (%) 20.3 + 2.2 6.3 + 2.9 ~' after 24 h drug administration with concurrent electrical stimu- 
- - lation of the left circumflex coronary artery. OKY-1581 was 
Total heart (g) 110.1_+7.4 114.1+_7 administered every" 4 h as a 1 mg/kg i.v. injection. ".', ~, 4 S.E.M. 
Mean _+ S.E.M. r, p < 0.05. treated vs. control. * P < 0.05 for 24 or 4 vs. 0 h. 
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IO0 its lack of acute hemodynamic effects during in- 
travenous administration. Our experimental design 
z 80 o did not provide for an assessment of the chronic 
g. '~ 60 hemodynamic effects of thromboxane synthetase "' inhibition since the studies were terminated at 24 h ct: 4 0  after the initiation of drug therapy. Preliminary 0~ 20 studies with dazoxiben have not revealed any clini- 
cally relevant changes in heart rate or blood pres- 
o sure during subacute administration in humans 
COLLAGEN ADP ARACHIDONIC 
ACID (Tyler et al., 1981). 
OKY-1581 treated animals maintained coro- 
Fig. 2. Each bar represents the mean + S.E.M. (n = 7) for an nary flow at the end of the experimental period in 
aggregating condition at one of three time points: 0 h, the 
pre-saline control (0.9% NaCI) baseline; 4 h, after the second c o n t r a s t  t o  control animals. While a direct rela- 
dose of saline control (0.8% NaCI) and 24 h, after 24 h of saline tionship of the size of the thrombus to the degree 
control (0.9% NaCI) administrat ion with concurrent electrical of coronary flow w a s  n o t  evident, large thrombi 
stimulation of the left circumflex coronary ar te~.  ~ R +_ S.E.M. w e r e  usually occlusive. 
We assume the reduction in coronary flow in 
this model to represent transient total occlusion of 
One animal in the control group died suddenly the circumflex artery due to intraluminal thrombi 
in the 1 l th h of electrical stimulation with ventric- which embolize spontaneously (Folts et al., 1982). 
ular fibrillation as the terminal arrhythmia. In the At some point, total occlusion may occur when a 
drug treated group, five of seven animals were "critical closing pressure" is reached due to 
arrhythmia-free including three animals with small thrombus causing a stenosis greater than 90% of 
areas of irreversibly injured myocardium as de- the circumflex diameter with or without superven- 
termined by histochemical staining with triphenyl- ing coronary vasomotor activity (Elzinga and 
tetrazolium. In the control animals, the ventricular Skinner, 1975; Burton, 1965; Uchida et al., 1975; 
arrhythmias typically were extended runs of Santamore et al., 1980). A recent study by Sellers 
ventricular tachycardia, occasionally multiform. In and Ku (1982) has demonstrated the ability of 
the drug treated group, the arrhythmias were thrombin to promote coronary artery vasoconstric- 
qualitatively similar, tion only after endothelial damage had been pro- 
OKY-1581 inhibited platelet aggregation in re- duced. A similar mechanism might be operative in 
sponse to standard aggregation conditions (fig. 1). the present study. Thus, the induction of endo- 
In comparing the 4 h and 24 h aggregations to the thelial injury by an electrical current and the sub- 
pre-drug baseline (0 h), significant inhibition of sequent development of platelet adhesion and 
aggregation was evident at each point for ADP thrombosis would bring about formation of 
and arachidonic acid. For the collagen aggregatory thrombin which could then cause coronary artery 
condition, a significant difference was evident only vasospasm which would convert a partially ob- 
at 24 h. structing platelet thrombus to a totally occlusive 
For the control animal, no significant dif- thrombus. This could account for our finding of a 
ferences were observed for any of the time points markedly decreased coronary artery flow despite 
for any of the aggregating conditions as compared the presence of a relatively small thrombus. Our 
to the baseline states (fig. 2). model does not differentiate whether the primary 
effect of OKY-1581 is due to antithrombotic or 
antispasmodic properties. However, the ability of 
4. Discussion nitroglycerin injection to restore the coronary flow 
pattern during the phasic oscillations in coronary 
OKY-1581, a thromboxane synthetase inhibi- flow would suggest that aggregation of platelets at 
tor, has no direct vascular effects as suggested by the site of injury can lead to coronary artery 
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vasomot ion  (Sellers and Ku, 1982; Romson  and fact that control  animals had no significant change 
Lucchesi,  1980). Main tenance  of coronary  flow in aggregation patterns during the experimental  
was most impor tant  in l imitat ion of infact size as period. 
animals  with small nonocclusive thrombi  had the 
smallest  infarctions.  Addi t ional  beneficial  effects 
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